Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’s FDA Submission Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’s FDA Submission
Originally posted here:
Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to...
Recommendation and review posted by Fredricko
